BACKGROUND: Guidelines suggest that patients on continuous antiretroviral therapy for >4 months with current viral load (VL)>1,000 copies/ml should be tested for resistance. There are limited data showing the frequency of resistance testing in routine clinical practice following these recommendations. METHODS: In EuroSIDA, virological failure (VF) was defined as confirmed VL>1,000 copies/ml after ≥ 4 months continuous use of any antiretroviral in a ≥ 3-drug regimen started during or after 2002. We assessed whether a resistance test was performed around VF (from 4 months before to 1 year after VF) and used logistic regression analysis to assess factors associated with having a resistance test. RESULTS: A total of 1,090 patients experienced VF a median 8.1 months (range 4 months to 6.3 years) after starting their regimen. There were 395 (36.2%; 95% CI 33.4-39.1) patients with a resistance test around the time of VF. Predictors of having a resistance test following VF include availability of a resistance test earlier than 4 months before VF (OR 2.20, 95% CI 1.77-2.75 for yes versus no; P<0.0001), region (OR 0.29, 95% CI 0.14-0.62 for Eastern Europe versus Northern Europe and OR 0.64, 95% CI 0.48-0.85 for Southern Europe versus Northern Europe; global P=0.0006) and current calendar year (OR 0.45, 95% CI 0.30-0.68 for ≥ 2007 versus 2004; global P=0.003). CONCLUSIONS: This analysis suggests a delay in genotypic testing after VF that seems longer than expected given current treatment guidelines. This delay is highly variable across Europe

Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA / Z.V. Fox, A. Cozzi-Lepri, A. d'Arminio Monforte, A. Karlsson, A.N. Phillips, G. Kronborg, J. Kjaer, B. Clotet, J.D. Lundgren, EuroSIDA. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 16:5(2011), pp. 781-785.

Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA

A. d'Arminio Monforte;
2011

Abstract

BACKGROUND: Guidelines suggest that patients on continuous antiretroviral therapy for >4 months with current viral load (VL)>1,000 copies/ml should be tested for resistance. There are limited data showing the frequency of resistance testing in routine clinical practice following these recommendations. METHODS: In EuroSIDA, virological failure (VF) was defined as confirmed VL>1,000 copies/ml after ≥ 4 months continuous use of any antiretroviral in a ≥ 3-drug regimen started during or after 2002. We assessed whether a resistance test was performed around VF (from 4 months before to 1 year after VF) and used logistic regression analysis to assess factors associated with having a resistance test. RESULTS: A total of 1,090 patients experienced VF a median 8.1 months (range 4 months to 6.3 years) after starting their regimen. There were 395 (36.2%; 95% CI 33.4-39.1) patients with a resistance test around the time of VF. Predictors of having a resistance test following VF include availability of a resistance test earlier than 4 months before VF (OR 2.20, 95% CI 1.77-2.75 for yes versus no; P<0.0001), region (OR 0.29, 95% CI 0.14-0.62 for Eastern Europe versus Northern Europe and OR 0.64, 95% CI 0.48-0.85 for Southern Europe versus Northern Europe; global P=0.0006) and current calendar year (OR 0.45, 95% CI 0.30-0.68 for ≥ 2007 versus 2004; global P=0.003). CONCLUSIONS: This analysis suggests a delay in genotypic testing after VF that seems longer than expected given current treatment guidelines. This delay is highly variable across Europe
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
serveFile.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 195.6 kB
Formato Adobe PDF
195.6 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/193311
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact